Bio­equi­va­lence Waiver for Lower Strengths of a BCS Class IV Drug [Regulatives / Guidelines]

posted by dshah  – India, 2025-07-07 13:07 (350 d 09:25 ago) – Posting: # 24407
Views: 2,670

Dear Praveen!

❝ Would it be acceptable to waive in vivo bioequivalence studies for the 60 mg and 80 mg strengths? Or, given the BCS Class IV designation, are BE studies still required for each individual strength?


It will be good to evaluate it based on dissolution and not just PK linearity/dose proportionality for lower strength Biowaiver.

Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
131 visitors (0 registered, 131 guests [including 37 identified bots]).
Forum time: 22:33 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5